Dementia Treatment Market By Product Type (Symptomatic Treatments [Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Symptomatic Medicines], Disease-Modifying Treatments [Anti-Amyloid Monoclonal Antibodies, Other Disease-Modifying Therapies]); By Application (Alzheimer’s Disease, Vascular Dementia, Dementia with Lewy Bodies, Frontotemporal Dementia, Mixed Dementia, Other Dementia Types); By End User (Hospitals, Neurology and Memory Clinics, Infusion Centers, Retail Pharmacies, Online Pharmacies, Home-Care Settings); By Route of Administration (Oral, Intravenous, Subcutaneous, Transdermal); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Dementia Treatment Market: Early Diagnosis, Reimbursement, and Easier Drug Delivery Shift Revenue Toward Disease-Modifying Care

The Global Dementia Treatment Market was valued at USD 11.79 billion in 2025 and is projected to reach USD 27.42 billion by 2032, growing at a CAGR of 12.8%, according to Strategic Market Research.

 

The dementia treatment market is moving beyond a prescription base dominated by low-cost symptomatic medicines. Revenue growth now depends on identifying Alzheimer’s disease earlier, confirming amyloid pathology, obtaining payer approval, and keeping patients on treatment without overwhelming specialist and imaging capacity. Suppliers that combine drugs with diagnostic support, reimbursement services, monitoring pathways, and simpler administration are gaining an advantage over companies competing only through pharmaceutical supply.

 

Approximately 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases each year. Alzheimer’s disease accounts for an estimated 60%–70% of dementia cases. These figures establish the long-term treatment need but do not represent the current addressable population for disease-modifying drugs. Leqembi and Kisunla are used in selected patients with mild cognitive impairment or mild dementia due to Alzheimer’s disease after amyloid pathology has been confirmed.

 

Generic Medicines Retain Patient Volume, While Biologics Capture More Revenue per Treatment

Donepezil, galantamine, rivastigmine, and memantine remain the main pharmaceutical treatments used across established dementia care. NICE recommends acetylcholinesterase inhibitors for mild to moderate Alzheimer’s disease and memantine for defined moderate or severe populations. These medicines reach a broader group than current anti-amyloid therapies because treatment can continue after patients move beyond the early disease stage.

Generic availability limits pricing power in this part of the market. Formularies and acquisition-cost rules encourage clinicians and health systems to use the lowest-cost clinically suitable product. Manufacturers compete through reliable supply, pharmacy availability, dosage options, and payer inclusion rather than through meaningful brand premiums.

Leqembi and Kisunla have introduced a higher-value model based on biomarker-confirmed early Alzheimer’s disease. Leqembi received traditional FDA approval in July 2023, followed by Kisunla in July 2024. Kisunla is administered every four weeks and may be discontinued after patients reach a defined level of amyloid clearance. Leqembi initially required continuing intravenous treatment but has since expanded into subcutaneous dosing.

Eisai set Leqembi’s U.S. annual list price at USD 26,500. Lilly published Kisunla course examples of USD 12,522 for six months, USD 32,000 for 12 months, and USD 48,696 for 18 months. These figures exclude amyloid testing, MRI scans, infusion administration, specialist consultations, and adverse-event management.

Each biologic initiation therefore generates revenue beyond the medicine itself. Neurology practices, memory clinics, diagnostic laboratories, imaging providers, infusion networks, specialty pharmacies, and patient-support services all participate in the treatment pathway. The higher revenue per patient is balanced by a much narrower eligible population and greater operational cost.

 

Diagnosis and Eligibility Losses Keep Treatment Volumes Below the Disease Burden

The United States had an estimated 7.1 million people living with Alzheimer’s symptoms in 2025, with the population projected to exceed 13.9 million by 2060. Only a small portion will enter disease-modifying treatment. Patients can leave the pathway because diagnosis occurs too late, amyloid testing is unavailable, safety risks are identified, payer approval is delayed, treatment centers lack capacity, or families decide that the burden outweighs the expected benefit.

Early Medicare utilization demonstrates the size of this loss. A JAMA Network Open study identified 1,725 Medicare fee-for-service beneficiaries who received lecanemab between July 2023 and March 2024. The comparison population included 842,192 beneficiaries with Alzheimer’s disease or mild cognitive impairment codes, producing an early uptake rate of 0.20%.

The comparison group included patients who would not meet all clinical eligibility criteria, but the result confirms that a recorded diagnosis is only the beginning of the commercial pathway. Biomarker confirmation, disease stage, MRI findings, comorbidities, patient preference, specialist availability, and coverage determine whether a prescription becomes a treatment initiation.

Treatment persistence also affects recurring revenue. The Medicare study found that 1,318 of the 1,725 identified users were still receiving lecanemab in March 2024. The remaining 407 patients had apparently discontinued by that point. Manufacturers and treatment networks must therefore track retention alongside new patient starts when planning drug supply, service capacity, and patient-support investment.

Access has also been concentrated among patients living near established treatment centers. Early Medicare users were 90.5% White, 88% urban, and only 1.3% socioeconomically disadvantaged. Wider adoption requires more than public awareness. Rural neurology capacity, minority access, supplemental insurance coverage, caregiver availability, and travel burden will influence how quickly the eligible population expands.

 

Leqembi and Kisunla Sales Confirm a Commercial Premium Segment

Leqembi generated USD 168 million in global in-market sales during the first quarter of 2026, an increase of 74% year over year. U.S. in-market sales reached USD 86 million. Kisunla generated USD 124 million during the same quarter, compared with USD 22 million in the first quarter of 2025.

The sales increase confirms that anti-amyloid treatment has developed into a measurable pharmaceutical category. Competition now extends beyond clinical efficacy. Treatment duration, administration frequency, safety monitoring, diagnostic access, payer support, physician confidence, and geographic reimbursement affect product adoption.

Aduhelm demonstrated how quickly commercial expectations can weaken when these conditions are not met. Biogen discontinued Aduhelm development and commercialization in 2024 and redirected resources toward Leqembi and other Alzheimer’s programs. Regulatory approval did not overcome uncertainty around clinical value, reimbursement, and provider willingness to build a treatment pathway.

Future products will need evidence that health systems can use in coverage decisions and routine practice. Modest clinical benefits may not support premium pricing when the full pathway also requires imaging, specialist staff, patient coordination, and adverse-event management.

 

Blood Tests Reduce the Cost of Finding Treatable Patients

Traditional amyloid confirmation through PET imaging or cerebrospinal fluid testing slows treatment decisions and concentrates access in specialist centers. Blood-based biomarkers are beginning to reduce that bottleneck.

The FDA cleared the first blood-based in vitro diagnostic intended to aid Alzheimer’s diagnosis in May 2025. Fujirebio’s Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio helps detect amyloid plaques in symptomatic adults aged 55 years and older. Clinicians must interpret the result with other patient information, but the test can reduce dependence on PET scans and lumbar punctures during initial evaluation.

Lower-cost testing can expand the number of patients screened without sending every candidate through expensive confirmatory procedures. Acumen Pharmaceuticals reported that a plasma pTau217 assay reduced overall screening costs by approximately 40% in its Phase 2 ALTITUDE-AD study across U.S. and Canadian sites. Clinical-trial screening differs from routine care, but the result provides evidence that blood biomarkers can remove unsuitable candidates earlier and improve the economics of patient identification.

Roche is building a combined pharmaceutical and diagnostic position. Its Elecsys pTau181 test received CE marking in 2025 to help rule out Alzheimer’s-associated amyloid pathology. The company’s pTau217 test received CE marking in May 2026 as a rule-in and rule-out aid. Roche is developing these products alongside trontinemab, giving it potential involvement in diagnosis, trial recruitment, treatment selection, and pharmaceutical delivery.

Drug manufacturers without diagnostic partnerships may face slower patient conversion, particularly in markets with limited PET capacity. Companies that help clinicians identify appropriate patients earlier can expand the treated population while reducing wasted testing and referral costs.

 

At-Home Administration Changes the Economics of Drug Delivery

Specialist capacity remains one of the largest constraints on anti-amyloid adoption. A U.S. memory clinic initiated lecanemab treatment in 234 patients over 14 months, equal to 5.9% of the 3,938 patients seen during the study period. The clinic required five full-time-equivalent employees dedicated to advanced practice care, nursing, coordination, medical assistance, and cognitive testing.

Staff managed insurance authorization, infusion scheduling, MRI surveillance, patient communication, and adverse-event follow-up. Amyloid-related imaging abnormalities were identified in 22% of 194 patients who received at least four infusions and underwent monitoring MRI. Most events were manageable, but treatment still required trained clinicians, standardized imaging, and rapid response protocols.

The FDA later recommended an additional MRI before the third Leqembi infusion. Additional monitoring supports demand for imaging services but raises the workload and total treatment cost for providers.

Subcutaneous Leqembi reduces part of the administration burden. Leqembi IQLIK received U.S. approval for maintenance dosing in 2025 and for treatment initiation in July 2026. Weekly at-home administration can reduce infusion-chair use, patient travel, and repeated hospital visits.

Home dosing does not remove the need for specialist diagnosis, amyloid confirmation, baseline imaging, safety monitoring, or payer approval. Revenue moves away from repeated infusion services toward pharmaceutical distribution, patient training, adherence support, remote coordination, and continued MRI surveillance. Infusion centers may lose some administration volume, while specialty pharmacies and home-treatment support providers gain a larger role.

 

Reimbursement Produces Different Commercial Outcomes from the Same Clinical Evidence

CMS provides the clearest reimbursement route for approved anti-amyloid medicines. Medicare covers qualifying monoclonal antibodies through Coverage with Evidence Development for patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia. Providers must participate in an approved registry or data-submission program.

Coverage gives manufacturers access to the largest U.S. payer population but adds administrative work for treatment sites. Original Medicare beneficiaries may also face 20% Part B coinsurance after the deductible unless supplemental insurance reduces their liability. Diagnostic expenses, travel, caregiver time, and monitoring costs can still prevent eligible patients from starting treatment.

England has taken a more restrictive approach. NICE’s March 2026 draft guidance continued to not recommend lecanemab for routine NHS use. The assessment cited uncertainty around long-term evidence, modest treatment benefit, acquisition cost, hospital infusion requirements, and intensive safety monitoring. NHS providers would also need to expand diagnostic, imaging, and specialist capacity before routine treatment could begin.

The European Commission authorized Leqembi in April 2025 and Kisunla in September 2025, but national health-technology assessments determine whether regulatory access becomes reimbursed demand. Countries with funded biomarker testing, established memory clinics, MRI availability, and negotiated biologic pricing can move faster than systems that must construct the treatment pathway before prescribing.

Manufacturers therefore need separate commercial strategies for approval, reimbursement, and provider implementation. A product can hold regulatory authorization across a region while generating limited revenue in countries where health systems consider the treatment benefit too small relative to total care costs.

 

Pipeline Developers Are Targeting Earlier Treatment and Lower Delivery Burden

Lilly is developing remternetug as a potential next-generation anti-amyloid treatment. Its Phase 3 TRAILRUNNER-ALZ 1 study enrolled approximately 1,667 participants with early symptomatic Alzheimer’s disease. Lilly is also studying the therapy before substantial clinical impairment, which could extend treatment into biomarker-positive populations that have not yet developed mild dementia.

Roche has moved trontinemab into Phase 3 development through the TRONTIER studies and is preparing the PrevenTRON study in cognitively unimpaired individuals with biomarkers associated with higher progression risk. Roche’s brain-delivery technology and diagnostic portfolio could reduce two separate barriers: identifying suitable patients and delivering sufficient drug into the brain.

Acumen’s sabirnetug targets soluble amyloid-beta oligomers and is being evaluated in the Phase 2 ALTITUDE-AD study. Top-line results are expected in late 2026. Acumen is also working with JCR Pharmaceuticals on brain-delivery technology intended to improve penetration.

These assets remain outside established commercial revenue. Their value will depend on whether they improve clinical outcomes, reduce imaging abnormalities, shorten treatment, simplify administration, or lower the cost of finding patients. Products that add only small efficacy gains without reducing pathway costs may struggle to secure favorable reimbursement.

 

U.S. Infrastructure Supports Faster Uptake Than Other Major Regions

North America holds the strongest near-term position because the United States combines a large Alzheimer’s population, approved disease-modifying drugs, Medicare coverage, expanding blood-test availability, and company-supported treatment networks. Leqembi and Kisunla sales confirm that providers are converting these conditions into treatment revenue, although access remains concentrated in urban and specialist settings.

Europe has a broad regulatory opportunity but fragmented reimbursement. National assessments can delay or prevent adoption after European authorization. Diagnostic requirements, genotype restrictions, and limited treatment infrastructure further narrow the eligible population.

Japan remains important because of its aging population and large early-stage assessment pool. Government-derived estimates identified 4.43 million older people with dementia and 5.59 million with mild cognitive impairment in 2022. These groups are not automatically eligible for anti-amyloid treatment, but they create a substantial base for diagnostic evaluation and specialist referral.

Low- and middle-income countries account for more than 60% of people living with dementia worldwide, while premium treatment infrastructure remains concentrated in wealthier markets. Limited specialist availability, biomarker testing, MRI access, public reimbursement, and biologic-delivery capacity will keep much of the global patient population outside the near-term disease-modifying treatment market.

 

Market Outlook

Generic oral medicines will continue to account for most treatment volume because they cover broader disease stages, require less infrastructure, and remain affordable to public and private payers. Revenue growth will be concentrated in early Alzheimer’s disease, where each treated patient generates spending across drugs, diagnostics, imaging, monitoring, and specialist care.

Blood-based biomarkers can enlarge the treatment funnel by reducing screening cost. At-home administration can remove part of the infusion bottleneck. Pipeline products may push treatment into earlier disease stages or improve brain delivery. Reimbursement will remain the final test of whether these clinical developments produce sustainable revenue.

Pharmaceutical companies that connect diagnosis, coverage, treatment delivery, safety monitoring, and patient persistence will convert more eligible patients than drug-only competitors. Market leadership will depend on reducing the losses between initial cognitive evaluation and sustained treatment without adding costs that payers and healthcare systems refuse to fund.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 11.79 Billion
Revenue Forecast in 2032	USD 27.42 Billion
Overall Growth Rate	CAGR of 12.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Route of Administration, By Geography
By Product Type	Symptomatic Treatments, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Symptomatic Medicines, Disease-Modifying Treatments, Anti-Amyloid Monoclonal Antibodies, Other Disease-Modifying Therapies
By Application	Alzheimer’s Disease, Vascular Dementia, Dementia with Lewy Bodies, Frontotemporal Dementia, Mixed Dementia, Other Dementia Types
By End User	Hospitals, Neurology and Memory Clinics, Infusion Centers, Retail Pharmacies, Online Pharmacies, Home-Care Settings
By Route of Administration	Oral, Intravenous, Subcutaneous, Transdermal
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, Germany, UK, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising dementia diagnosis rates, wider adoption of disease-modifying therapies, growing use of anti-amyloid monoclonal antibodies, expanding neurology and memory clinic networks, stronger demand for early intervention and long-term cognitive care
Customization Option	Available upon request